FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8132人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839849, encodeId=d5741839849b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, objectType=article, longId=197593, objectId=979d19e59394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979d19e59394, replyNumber=0, likeNumber=86, createdTime=2021-02-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979d19e59394, moduleTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979d19e59394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839877, encodeId=c73218398e772, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, objectType=article, longId=201903, objectId=4d5c201903de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d5c201903de, replyNumber=0, likeNumber=67, createdTime=2020-11-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d5c201903de, moduleTitle=美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d5c201903de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839820, encodeId=b94918398200c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=全球**非激素避孕药Phexxi，获得FDA批准, objectType=article, longId=194630, objectId=1bb11946306f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb11946306f, replyNumber=0, likeNumber=61, createdTime=2020-10-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb11946306f, moduleTitle=全球**非激素避孕药Phexxi，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb11946306f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839792, encodeId=229e1839e9230, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=40, createdTime=2021-02-22, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839783, encodeId=6f761839e83c3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=98, createdTime=2020-10-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839775, encodeId=23111839e7574, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市, objectType=article, longId=189172, objectId=81241891e2b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81241891e2b4, replyNumber=0, likeNumber=61, createdTime=2020-08-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81241891e2b4, moduleTitle=Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81241891e2b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839865, encodeId=993c18398652b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, objectType=article, longId=199785, objectId=1282199e85f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1282199e85f7, replyNumber=0, likeNumber=124, createdTime=2021-03-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1282199e85f7, moduleTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1282199e85f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839844, encodeId=cac1183984429, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi, objectType=article, longId=197031, objectId=57f219e03170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f219e03170, replyNumber=0, likeNumber=57, createdTime=2020-08-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f219e03170, moduleTitle=FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57f219e03170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839840, encodeId=73ab18398406c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, objectType=article, longId=196815, objectId=70ef1968157f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef1968157f, replyNumber=0, likeNumber=60, createdTime=2020-10-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef1968157f, moduleTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ef1968157f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症, objectType=article, longId=196587, objectId=ffa019658e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa019658e05, replyNumber=0, likeNumber=70, createdTime=2020-12-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa019658e05, moduleTitle=FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa019658e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839880, encodeId=0383183988071, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, objectType=article, longId=202168, objectId=22ff2021685a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ff2021685a, replyNumber=0, likeNumber=0, createdTime=2021-04-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ff2021685a, moduleTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ff2021685a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839825, encodeId=6e89183982518, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准, objectType=article, longId=195464, objectId=7a1c19546415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a1c19546415, replyNumber=0, likeNumber=57, createdTime=2020-09-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a1c19546415, moduleTitle=间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a1c19546415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839860, encodeId=c3a91839860b4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=重度抑郁症新药获FDA批准——强生的鼻喷雾剂Spravato, objectType=article, longId=198727, objectId=cff5198e2791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cff5198e2791, replyNumber=0, likeNumber=77, createdTime=2021-06-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cff5198e2791, moduleTitle=重度抑郁症新药获FDA批准——强生的鼻喷雾剂Spravato, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff5198e2791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839875, encodeId=4d8418398e549, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, objectType=article, longId=201577, objectId=bce42015e75f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce42015e75f, replyNumber=0, likeNumber=67, createdTime=2021-07-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce42015e75f, moduleTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce42015e75f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839853, encodeId=694c1839853ab, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Breztri Aerosphere单一吸入器给药的三联疗法：治疗慢性阻塞性肺病COPD获FDA批准, objectType=article, longId=198017, objectId=f97319801e09, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f97319801e09, replyNumber=0, likeNumber=71, createdTime=2021-03-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f97319801e09, moduleTitle=Breztri Aerosphere单一吸入器给药的三联疗法：治疗慢性阻塞性肺病COPD获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f97319801e09)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839848, encodeId=63d8183984860, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, objectType=article, longId=197391, objectId=8b4a19e3919e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4a19e3919e, replyNumber=0, likeNumber=77, createdTime=2021-05-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4a19e3919e, moduleTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4a19e3919e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=75, createdTime=2020-11-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839751, encodeId=8f061839e51fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了新的甲氨蝶呤注射制剂RediTrex用于治疗类风湿关节炎, objectType=article, longId=184296, objectId=9b4818429678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b4818429678, replyNumber=0, likeNumber=56, createdTime=2020-02-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b4818429678, moduleTitle=FDA批准了新的甲氨蝶呤注射制剂RediTrex用于治疗类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b4818429678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839854, encodeId=1555183985423, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=0, createdTime=2021-06-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839826, encodeId=c66518398261d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=61, createdTime=2020-07-10, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）

2021-02-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准欧狄沃联合伊匹木单抗用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者，成为且目前**获批的免疫疗法

2020-11-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

全球**非激素避孕药Phexxi，获得FDA批准

2020-10-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2021-02-22

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-10-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市

2020-08-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次

2021-03-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准长链脂肪酸氧化代谢病的最佳治疗药物——Dojolvi

2020-08-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法

2020-10-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症

2020-12-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者

2021-04-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

间充质干细胞BX-U001治疗风湿性关节炎的IND申请，获得FDA批准

2020-09-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

重度抑郁症新药获FDA批准——强生的鼻喷雾剂Spravato

2021-06-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤

2021-07-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Breztri Aerosphere单一吸入器给药的三联疗法：治疗慢性阻塞性肺病COPD获FDA批准

2021-03-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

2021-05-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2020-11-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了新的甲氨蝶呤注射制剂RediTrex用于治疗类风湿关节炎

2020-02-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2021-06-27

一叶知秋 (审核中...)

前往app查看评论内容

#FDA批准#

BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌

2020-07-10

科室
- - 订阅+
  - 更多科室
工具
服务